A CRISPR path to drug discovery

Nature

Volumn 555, Issue 7695, 2018, Pages S10-S11

  Scott, Andrew ^a  

^a Perth Academy   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN; CRISPR ASSOCIATED PROTEIN; DOUBLE STRANDED DNA; RNA;

BACTERIUM; DRUG DEVELOPMENT; ENZYME ACTIVITY; GENETIC ANALYSIS; IMMUNE SYSTEM; METABOLISM; NUCLEIC ACID;

CRISPR CAS SYSTEM; DISEASE MODEL; DNA MODIFICATION; DNA REPAIR; DNA SEQUENCE; DRUG DEVELOPMENT; DRUG RESEARCH; DRUG RESISTANCE; DRUG TARGETING; GENE EDITING; GENE KNOCKOUT; GENE MUTATION; GENETIC ENGINEERING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SHORT SURVEY; ANIMAL; GENETICS; MOLECULARLY TARGETED THERAPY; PROCEDURES; TRENDS;

ANIMALS; CRISPR-CAS SYSTEMS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG RESISTANCE; GENE EDITING; GENE KNOCKOUT TECHNIQUES; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 85043471061     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/d41586-018-02477-1     Document Type: Short Survey

References (3)

1. Fellmann, C., Gowen, B. G., Lin, P. C., Doudna, J. A. & Corn, J. E. Nature Rev. Drug Discov. 16, 89-100 (2017).
2. Murovec, J., Pirc, Ž. & Yang, B. Plant Biotechnol. J. 15, 917-926 (2017).
3. Oakes, B. L. et al. Nature Biotechnol. 34, 646-651 (2016).